Articles tagged with “health-economics”

Examine AI in pharma HEOR and real-world evidence. This report details how machine learning and RWD advance health economic modeling and regulatory decisions.

Updated May 2026. Learn about value-based contracting (VBC) in pharma, including the CMS Cell and Gene Therapy Access Model, IRA negotiated prices, and outcomes-based agreements for Casgevy, Lyfgenia, Beqvez, and Roctavian.

Efficacy in clinical trials often overstates real-world effectiveness. Learn why this gap exists and how HEOR uses real-world evidence (RWE) to correct for it.

An educational guide to QALYs and ICERs, the core metrics in health economics. Learn how they measure value and guide cost-effectiveness decisions. Updated April 2026 with NICE's new £25k–£35k/QALY threshold.

Updated April 2026: Million-dollar gene therapy pricing analysis covering Casgevy, Lyfgenia, Lenmeldy, Elevidys (with 2025 safety update), the Roctavian and Beqvez market withdrawals, and CMS's 2025 Cell and Gene Therapy Access Model. Compares one-time cure costs to lifetime chronic care using value-based pricing, ICER QALY thresholds, and outcomes-based contracts.

Learn how patient quality of life (QoL) data is quantified into Quality-Adjusted Life Years (QALYs) to perform cost-effectiveness analysis for specialty drugs.

How real-world data (RWD) and evidence (RWE) validate clinical trial assumptions in post-market economic models. Updated April 2026 with EU JCA, DARWIN EU, FDA finalized RWE guidance, ICH M14 and EHDS developments.

Learn how health economic data like cost-effectiveness analysis is used to secure drug formulary placement and reimbursement from payers and HTA bodies.

An overview of market access analytics covering its definition, scope, and role in helping pharmaceutical firms navigate complex payer reimbursement models. Updated for 2026 with IRA drug price negotiation impacts, agentic AI platforms, EU HTA harmonisation, and digital therapeutics reimbursement advances.